Quarter-Sized implant could free type 1 diabetes patients from daily insulin

NCT ID NCT07680673

Not yet recruiting Disease control Sponsor: Encellin Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This early-stage trial tests a small, soft implant that holds donor insulin-making cells (islets) and protects them from the immune system. The goal is to see if the device is safe and keeps the cells alive and working in adults with type 1 diabetes. Some participants are also on the standard waitlist for islet infusions, while others are not. The implant stays in for about 4 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ENCRT-103-hPI (encapsulated human islet cells in a protective device)
What this could lead to: If successful, this approach could allow people with type 1 diabetes to produce their own insulin without needing lifelong immunosuppression.
What could go wrong: This is a very early Phase 1 trial with only 10 participants, so safety and basic function are the main focus. The implant may not produce enough insulin or could cause side effects like scarring or rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

McGill University Health Centre

Montreal, Quebec, Canada
UHN

Toronto, Ontario, Canada
Vancouver General Hospital

Vancouver, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.